Community Corner

In an effort to foster the highest level of transparency between pharmaceutical companies and the AS community, FAST welcomes and hosts a robust channel of communication for all stakeholders. All such news is archived here for public access.

• Roche on discontinuation of rugonersen (RO7248824) in Angelman syndrome, 2023

• Ultragenyx Responds to Roche Update

• Ultragenyx Receives FDA Agreement to Expand Trials in US

• Community Statement from IONIS

• Science and Pharmaceutical Video Updates